Background

Madeline’s key interests lie in drug discovery, particularly in the malaria parasite plasmodium falciparum. Using compounds from the phenotypic screens, Madeline hopes to gain insight into parasite invasion of host red blood cells, which will better our understanding of this key process and aid future antimalarial development.

Positions

• 2018: PhD Student
• 2017: Research Assistant, School of Medicine, Deakin University

Qualifications

• 2016: BSc (Hons), University of Melbourne, Australia

Awards

• Boehringer Ingelheim Fonds travel grant, 2019
• Victorian Infection & Immunity Network Lorne Conference Best Poster, 2019

Publications (4)

2021 (1)

• Structure activity refinement of phenylsulfonyl piperazines as antimalarials that block erythrocytic invasion.
  Nguyen W, Dans MG, Ngo A, Gancheva MR, Romeo O, Duffy S, de Koning-Ward TF, Lowes KN, Sabroux HJ, Avery VM, Wilson DW, Gilson PR, Sleebs BE
  Eur J Med Chem. 2021 Feb; 214:113253

2020 (1)

• Screening the Medicines for Malaria Venture Pathogen Box for invasion and egress inhibitors of the blood stage of Plasmodium falciparum reveals several inhibitory compounds.
  Dans MG, Weiss GE, Wilson DW, Sleebs BE, Crabb BS, de Koning-Ward TF, Gilson PR
  Int J Parasitol. 2020 Mar; 50(3):235-252

2019 (2)

• A 4-cyano-3-methylisoquinoline inhibitor of Plasmodium falciparum growth targets the sodium efflux pump PfATP4.
  Gilson PR, Kumarasingha R, Thompson J, Zhang X, Penington JS, Kalhor R, Bullen HE, Lehane AM, Dans MG, de Koning-Ward TF, Holien JK, Soares da Costa TP, Hulett MD, Buskes MJ, Crabb BS, Kirk K, Papenfuss AT, Cowman AF, Abbott BM
  Sci Rep. 2019 Jul; 9(1):10292
• Targeting malaria parasite invasion of red blood cells as an antimalarial strategy.
  Burns AL, Dans MG, Balbin JM, deKoning-Ward T, Gilson PR, Beeson JG, Boyle MJ, Wilson DW
  FEMS Microbiol Rev. 2019 May; 43(3):223-228

News Articles (1)

2020 (1)

• Burnet Institute Travel Awards